Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
NANJING, China, Sept. 1, 2026 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into an exclusive global licensing agreement with Roche for the development and commercialization of SIM0660, a tri-specific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases. Under the terms of the agreement, Roche...
Time is Running Out to Submit a Claim in the Asbestos Corporation Limited insolvency proceedings
The deadline is September 10, 2026. NEW YORK, Sept. 1, 2026 /PRNewswire/ -- The following statement is being issued by Kroll Restructuring Administration and Raymond Chabot Inc. regarding the Asbestos Corporation Limited insolvency proceedings. With less than one month remaining before the September 10, 2026 Claims Bar Date, anyone with an asbestos-related claim against ACL, including heirs and representatives of...
QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery
Joint test on IonQ Forte hardware lands within 4% of benchmark, clearing the chemical-accuracy bar for enzyme active-site modeling via Amazon Braket PALO ALTO, Calif., Sept. 1, 2026 /PRNewswire/ -- QC Ware today announced a technology demonstration of a hybrid quantum-classical chemistry workflow using its Promethium® platform and IonQ's Forte trapped-ion...
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Paxalisib Into a Phase 2 Clinical Study to Evaluate Paxalisib in...
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expected By Year-End 2026 and Full Enrollment by End of 2027 SYDNEY, Sept. 1, 2026 /PRNewswire/...
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades of legal, intellectual property, corporate, and strategic experience across...
Siemens Healthineers showcases its AI-powered technological innovations to redefine healthcare delivery in Southeast Asia
Spotlights how scaling AI and big data can make clinical pathways more efficient Hosts its second ASEAN CEO Summit to drive collaboration amongst healthcare leaders to redefine care delivery in Southeast Asia Unveils new regional report "Strengthening Stroke System Readiness Across ASEAN" BANGKOK, Sept. 1, 2026 /PRNewswire/ -- At this year's Hospital Management Asia (HMA) healthcare...
Singapore is the first ASEAN country to provide government subsidy for eligible patients receiving vutrisiran for transthyretin amyloidosis
"From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75%," "HELIOS-A and B provide strong clinical evidence supporting improved patient outcomes" SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Medison Pharma (Medison), the creator of a first-of-its-kind unified global commercialisation platform for breakthrough therapies, today announced that...
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the closing of its...
Bausch Health Announces Availability of Solta Medical’s Fraxel FTX® in Australia
The next generation in skin resurfacing technology is available to Australian health care practitioners beginning 1 September 2026 LAVAL, QC, Sept. 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today announced the availability of Fraxel FTX® in...
